HK1125051A1 - Virus-like particles as vaccines for paramyxovirus - Google Patents
Virus-like particles as vaccines for paramyxovirusInfo
- Publication number
- HK1125051A1 HK1125051A1 HK09103268.0A HK09103268A HK1125051A1 HK 1125051 A1 HK1125051 A1 HK 1125051A1 HK 09103268 A HK09103268 A HK 09103268A HK 1125051 A1 HK1125051 A1 HK 1125051A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- virus
- particles
- vlps
- vaccines
- paramyxovirus
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 241000711404 Avian avulavirus 1 Species 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18423—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18523—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18623—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70612605P | 2005-08-05 | 2005-08-05 | |
US11/497,888 US7951384B2 (en) | 2005-08-05 | 2006-08-02 | Virus-like particles as vaccines for paramyxovirus |
PCT/US2006/030319 WO2007019247A2 (en) | 2005-08-05 | 2006-08-03 | Virus-like particles as vaccines for paramyxovirus |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1125051A1 true HK1125051A1 (en) | 2009-07-31 |
Family
ID=37727898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09103268.0A HK1125051A1 (en) | 2005-08-05 | 2009-04-07 | Virus-like particles as vaccines for paramyxovirus |
Country Status (14)
Country | Link |
---|---|
US (2) | US7951384B2 (zh) |
EP (1) | EP1917033B1 (zh) |
JP (2) | JP5342234B2 (zh) |
KR (1) | KR101120784B1 (zh) |
CN (1) | CN101282744B (zh) |
AT (1) | ATE528016T1 (zh) |
AU (1) | AU2006278588A1 (zh) |
BR (1) | BRPI0614702A2 (zh) |
CA (1) | CA2617508C (zh) |
HK (1) | HK1125051A1 (zh) |
IL (1) | IL189313A (zh) |
NZ (1) | NZ565961A (zh) |
RU (1) | RU2008106445A (zh) |
WO (1) | WO2007019247A2 (zh) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1913138B1 (en) | 2005-07-29 | 2016-08-24 | Abbott Laboratories GmbH | Processes for the manufacture of pancreatin powder with low virus content |
US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
WO2008061243A2 (en) * | 2006-11-16 | 2008-05-22 | Novavax, Inc. | Respiratory syncytial virus-virus like particle (vlps) |
CA2678966A1 (en) * | 2007-02-21 | 2008-08-28 | Novavax, Inc. | Chimeric newcastle disease virus vlps |
SI2540312T1 (sl) * | 2007-07-19 | 2015-08-31 | Novavax, Inc. | Ptičji influenčni himerni VLP |
EP2217699A4 (en) * | 2007-10-22 | 2012-11-28 | Univ Rochester | VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS BASED ON CAPSOMERS OR CHIMERIC PARTICLES SIMILAR TO PAPILLOMAVIRUS VIRUS |
WO2009060440A1 (en) * | 2007-11-05 | 2009-05-14 | Mor Research Applications Ltd. | Anti-measles cancer immunotherapy |
US20090130063A1 (en) * | 2007-11-15 | 2009-05-21 | Solvay Pharmaceuticals Gmbh | Process for separating and determining the viral load in a pancreatin sample |
WO2009132195A1 (en) * | 2008-04-23 | 2009-10-29 | Michigan State University | Immortal avian cell line and methods of use |
JP2010122205A (ja) * | 2008-08-29 | 2010-06-03 | Sysmex Corp | 麻疹ウイルス検出方法、メンブレンアッセイ用試験具およびメンブレンアッセイ用試験キット |
US8580270B2 (en) * | 2008-09-30 | 2013-11-12 | University Of Massachusetts | Respiratory synctial virus (RSV) sequences for protein expression and vaccines |
SG172022A1 (en) * | 2008-12-09 | 2011-07-28 | Novavax Inc | Modified rsv f proteins and methods of their use |
CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
US8871220B2 (en) * | 2009-04-03 | 2014-10-28 | Merial Limited | Newcastle disease virus vectored avian vaccines |
ES2563730T3 (es) * | 2009-07-15 | 2016-03-16 | Glaxosmithkline Biologicals S.A. | Composiciones de proteína RSV F y procedimientos de fabricación de las mismas |
EP2453903B1 (en) * | 2009-07-17 | 2016-08-17 | Industry Academic Cooperation Foundation, Hallym University | Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes |
US20110097358A1 (en) * | 2009-10-12 | 2011-04-28 | Techno Vax, Inc. | RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs) |
US10633667B2 (en) * | 2009-12-28 | 2020-04-28 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant NDV antigen and uses thereof |
EP3248615A1 (en) | 2010-03-30 | 2017-11-29 | Mount Sinai School of Medicine of New York University | Influenza virus vaccines and uses thereof |
HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
CA2804492A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation of large mammals with low doses of rna |
WO2012006378A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Liposomes with lipids having an advantageous pka- value for rna delivery |
PT4066856T (pt) | 2010-08-31 | 2023-01-02 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para entrega de arn codificador de imunogénio |
CN103269713B (zh) * | 2010-10-11 | 2016-01-20 | 诺华有限公司 | 抗原递送平台 |
JP2014522842A (ja) | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
CA2849434A1 (en) | 2011-09-20 | 2013-03-28 | Mount Sinai School Of Medicine | Influenza virus vaccines and uses thereof |
KR101374192B1 (ko) * | 2011-12-21 | 2014-03-14 | 대한민국 | 제4형 조류파라믹소바이러스 hn 단백질 및 이를 포함하는 hi법 검사용 항원진단액 |
US9458196B2 (en) | 2012-02-14 | 2016-10-04 | Council Of Scientific & Industrial Research | Synthetic peptides capable of binding to influenza hemagglutinin protein |
CN102618668B (zh) * | 2012-03-27 | 2013-08-28 | 广西壮族自治区兽医研究所 | 鸭新城疫病毒和鸭圆环病毒二重pcr检测试剂盒 |
US9968670B2 (en) | 2012-12-18 | 2018-05-15 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
CN113322264B (zh) | 2013-03-14 | 2024-05-31 | 爱默蕾大学 | 具有沉默突变的重组rsv、其相关疫苗和方法 |
KR101546064B1 (ko) | 2013-07-29 | 2015-08-20 | 건국대학교 산학협력단 | 인플루엔자 바이러스 매트릭스 1 단백질과 뉴캣슬 병 바이러스 융합 단백질을 발현하는 뉴캣슬 병 바이러스 바이러스 유사입자 |
CN104721817B (zh) * | 2013-12-19 | 2018-04-17 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
CN103805600A (zh) * | 2014-03-06 | 2014-05-21 | 福州大学 | 一种dna分子克隆方法 |
EP3247389A4 (en) | 2015-01-23 | 2019-10-30 | Icahn School of Medicine at Mount Sinai | INFLUENZAVIRUSSCHUTZIMPFPLÄNE |
WO2016149384A1 (en) | 2015-03-18 | 2016-09-22 | University Of Massachusetts | Virus-like particle compositions and vaccines against epstein-barr virus infection and disease |
WO2017087550A1 (en) * | 2015-11-16 | 2017-05-26 | Georgia State University Research Foundation, Inc. | Tunable vaccine platform against pathogens of the paramyxovirus family |
EP3389700B1 (en) * | 2015-12-17 | 2020-11-04 | The Penn State Research Foundation | Paramyxovirus virus-like particles as protein delivery vehicles |
EP3246410A1 (en) | 2016-05-19 | 2017-11-22 | Klinikum rechts der Isar der Technischen Universität München | Vsv/ndv hybrid viruses for oncolytic therapy of cancer |
EP3255056A1 (en) * | 2016-06-06 | 2017-12-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Method for producing self-assemblying paramyxoviral nucleocapsid-like particles and their uses |
JP7237344B2 (ja) | 2016-06-15 | 2023-03-13 | アイカーン スクール オブ メディシン アット マウント サイナイ | インフルエンザウイルス血球凝集素タンパク質及びその使用 |
WO2018067300A1 (en) | 2016-10-03 | 2018-04-12 | University Of Massachusetts | Methods for immunizing pre-immune subjects against respiratory syncytial virus (rsv) |
CN106636015B (zh) * | 2016-12-20 | 2019-12-10 | 吉林大学 | 一种嵌合型新城疫病毒样颗粒的制备方法 |
MA47790A (fr) * | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
WO2018187706A2 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
EP3856240A4 (en) | 2018-09-24 | 2022-09-28 | University of Massachusetts | COMPOSITIONS AND METHODS OF MANUFACTURE AND USE OF VIRUS-LIKE PARTICLES (VLPS) |
US11390853B2 (en) | 2019-04-26 | 2022-07-19 | Case Western Reserve University | Freeze dried viral nanoparticle constructs |
CN110628724B (zh) * | 2019-09-25 | 2023-04-14 | 兰州生物制品研究所有限责任公司 | 一种三型副流感病毒野毒株及其应用 |
CN112500494B (zh) * | 2020-11-09 | 2023-01-24 | 昆明市妇幼保健院 | 用于新型冠状病毒检测的抗原及其制备方法 |
AU2022208435A1 (en) | 2021-01-18 | 2023-08-10 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
CN113214366B (zh) * | 2021-05-25 | 2023-03-03 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一种重组新城疫病毒基质蛋白及其应用 |
CN114574452B (zh) * | 2021-12-29 | 2023-07-21 | 扬州大学 | Hn基因易位构建重组新城疫疫苗候选株vii-hnf的方法及用途 |
CN116479175A (zh) * | 2023-03-13 | 2023-07-25 | 广州国家实验室 | 用于检测人副流感病毒核酸的检测系统、试剂盒及方法 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2518755B1 (fr) | 1981-12-23 | 1986-04-11 | Pasteur Institut | Sonde contenant un acide nucleique modifie et reconnaissable par des anticorps specifiques et utilisation de cette sonde pour detecter et caracteriser une sequence d'adn homologue |
US6022958A (en) | 1986-08-13 | 2000-02-08 | Bayer Corporation | cDNAs coding for members of the carcinoembryonic antigen family |
US4774339A (en) | 1987-08-10 | 1988-09-27 | Molecular Probes, Inc. | Chemically reactive dipyrrometheneboron difluoride dyes |
US5631154A (en) | 1988-06-10 | 1997-05-20 | Therion Biologics, Incorporated | Self assembled, defective, non-self-propagating lentivirus particles |
US5250431A (en) | 1988-06-13 | 1993-10-05 | Dana-Farber Cancer Institute, Inc. | Alteration of the interaction of a T-cell receptor with a proteintyrosine kinase |
US5486599A (en) | 1989-03-29 | 1996-01-23 | The Board Of Trustees Of The Leland Stanford Junior University | Construction and use of synthetic constructs encoding syndecan |
US5690938A (en) | 1989-07-07 | 1997-11-25 | Oravax, Inc. | Oral immunization with multiple particulate antigen delivery system |
GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
US5433896A (en) | 1994-05-20 | 1995-07-18 | Molecular Probes, Inc. | Dibenzopyrrometheneboron difluoride dyes |
US5274113A (en) | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
US5589372A (en) | 1990-09-26 | 1996-12-31 | E. R. Squibb & Sons, Inc. | Squalene synthetase |
US5248782A (en) | 1990-12-18 | 1993-09-28 | Molecular Probes, Inc. | Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes |
US5187288A (en) | 1991-05-22 | 1993-02-16 | Molecular Probes, Inc. | Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis |
US5344760A (en) | 1991-06-03 | 1994-09-06 | Ciba Corning Diagnostics Corp. | Method of cancer detection |
US5847096A (en) | 1991-08-30 | 1998-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | DNA constructs encoding CD4 fusion proteins |
AU675416B2 (en) | 1991-11-01 | 1997-02-06 | Joslin Diabetes Center | Antigen associated with type I diabetes mellitus |
US5348867A (en) | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
ATE318902T1 (de) | 1992-12-31 | 2006-03-15 | Immulogic Pharma Corp | Allergene proteine und peptide von hundhautanhangsgebilden und ihre verwendung |
ATE180407T1 (de) | 1993-01-11 | 1999-06-15 | Dana Farber Cancer Inst Inc | Induktion der antworten zytotoxischer t- lymphozyten |
WO1994016081A1 (de) | 1993-01-16 | 1994-07-21 | Manfred Schawaller | Verfahren zur gewinnung nativer domänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv |
US6991797B2 (en) | 1993-07-02 | 2006-01-31 | Statens Serum Institut | M. tuberculosis antigens |
AUPM368994A0 (en) | 1994-02-04 | 1994-02-24 | Saramane Pty Ltd | Malaria merozoite antigen subunit vaccine |
US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
FR2717498B1 (fr) | 1994-03-18 | 1996-05-03 | Commissariat Energie Atomique | Transcrits du gène de CMH de classe I HLA-G et leurs applications. |
US5851993A (en) | 1994-06-13 | 1998-12-22 | Biotie Therapies Ltd. | Suppression of tumor cell growth by syndecan-1 ectodomain |
US5583816A (en) | 1994-06-29 | 1996-12-10 | Sgs-Thomson Microelectronics, Inc. | Long write test |
US6291157B1 (en) | 1998-02-23 | 2001-09-18 | Connaught Laboratories Limited | Antigenically-marked non-infectious retrovirus-like particles |
US6080408A (en) | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
US6689367B1 (en) | 1995-09-27 | 2004-02-10 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences |
US6713066B1 (en) | 1996-07-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 |
US6913881B1 (en) | 1996-01-24 | 2005-07-05 | Third Wave Technologies, Inc. | Methods and compositions for detecting target sequences |
US6699476B1 (en) | 1996-07-15 | 2004-03-02 | Peter L. Collins | Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules |
ATE423204T1 (de) | 1996-11-08 | 2009-03-15 | Us Gov Health & Human Serv | Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln |
US5916879A (en) | 1996-11-12 | 1999-06-29 | St. Jude Children's Research Hospital | DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof |
DE69833545T2 (de) | 1997-03-26 | 2006-12-14 | Imperial College Innovations Ltd. | In der zellmembran verankertes antikoagulant-fusionsprotein |
US7037510B2 (en) | 1997-04-18 | 2006-05-02 | Statens Serum Institut | Hybrids of M. tuberculosis antigens |
US7250171B1 (en) | 1997-05-23 | 2007-07-31 | United States Of America As Represented By The Dept. Of Health & Human Services | Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein |
CN100489105C (zh) | 1997-08-05 | 2009-05-20 | 恩温塔生物制药学公司 | 包含hpv抗原和应激蛋白或者其表达载体的组合物激发的抗hpv抗原免疫应答 |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
US7105488B1 (en) | 1998-02-27 | 2006-09-12 | The United States Of America As Represented By The Department Of Health And Human Services | G protein-coupled receptor antagonists |
EP0974660A1 (en) * | 1998-06-19 | 2000-01-26 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Newcastle disease virus infectious clones, vaccines and diagnostic assays |
US6248327B1 (en) | 1998-09-11 | 2001-06-19 | Vanderbilt University | Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis |
US6355786B1 (en) | 1998-10-30 | 2002-03-12 | Vanderbilt University | Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same |
EP1980617A1 (en) | 1998-12-31 | 2008-10-15 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
DE19906096A1 (de) | 1999-02-13 | 2000-08-17 | Walter Sebald | Protein mit einem Heparin-bindenden Epitop |
WO2000055181A1 (en) | 1999-03-15 | 2000-09-21 | The General Hospital Corporation | Methods of modulating cell attachment and migration |
US20030224017A1 (en) | 2002-03-06 | 2003-12-04 | Samal Siba K. | Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors |
US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US6306628B1 (en) | 1999-08-25 | 2001-10-23 | Ambergen, Incorporated | Methods for the detection, analysis and isolation of Nascent proteins |
US7119165B2 (en) | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
US20040105871A1 (en) | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
EP1156111A1 (en) | 2000-05-19 | 2001-11-21 | Stichting Dienst Landbouwkundig Onderzoek | Chimeric arterivirus-like particles |
PT1294771E (pt) | 2000-06-12 | 2009-01-06 | Univ Saskatchewan | Proteína gapc quimérica de streptococcus e sua utilização em vacinação e diagnóstico |
AUPQ841800A0 (en) | 2000-06-28 | 2000-07-20 | Biomolecular Research Institute Limited | Truncated egf receptor |
WO2002012454A1 (fr) | 2000-08-08 | 2002-02-14 | The Kitasato Institute | Micrograins de type viral et procede de production correspondant |
US6942866B2 (en) | 2000-08-16 | 2005-09-13 | Apovia, Inc. | Malaria immunogen and vaccine |
JP2002079971A (ja) * | 2000-09-06 | 2002-03-19 | Honda Motor Co Ltd | 車両用ウインドシールド |
AU2002306896B2 (en) | 2001-03-26 | 2007-04-26 | Walter Reed Army Institute Of Research | Plasmodium falciparum AMA-1 protein and uses thereof |
US7029685B2 (en) | 2001-03-26 | 2006-04-18 | The United States Of America As Represented By The Secretary Of The Army | Plasmodium falciparum AMA-1 protein and uses thereof |
WO2002081655A2 (en) | 2001-03-28 | 2002-10-17 | Children's Medical Center Corporation | Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo |
JP4261195B2 (ja) | 2001-04-24 | 2009-04-30 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 酵母のコア−グリコシル化されたhcvエンベロープタンパク質の発現 |
AU2002314895A1 (en) | 2001-06-07 | 2002-12-23 | Rigel Pharmaceuticals, Inc. | Letm1: modulators of cellular proliferation |
US6695545B2 (en) | 2001-10-11 | 2004-02-24 | Gregory M. Boston | Soil stabilization composition |
US7101566B2 (en) | 2002-06-28 | 2006-09-05 | Ethicon, Inc. | Polymer coated microparticles for sustained release |
EP1624890B1 (en) | 2003-01-24 | 2011-07-13 | University Of Massachusetts Medical Center | Identification of vaccinia virus dominant t cell epitopes |
US20050002953A1 (en) | 2003-05-06 | 2005-01-06 | Jens Herold | SARS-coronavirus virus-like particles and methods of use |
AU2004238843B2 (en) | 2003-05-09 | 2009-04-23 | Research Development Foundation | Insertion of furin protease cleavage sites in membrane proteins and uses thereof |
US7189403B2 (en) | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
JP2007527225A (ja) | 2003-07-30 | 2007-09-27 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Epha2t−細胞エピトープアゴニストおよびその使用 |
EP1660686B1 (en) | 2003-09-05 | 2012-05-09 | Genencor International, Inc. | Hpv cd8+ t-cell epitopes |
CA2678966A1 (en) * | 2007-02-21 | 2008-08-28 | Novavax, Inc. | Chimeric newcastle disease virus vlps |
-
2006
- 2006-08-02 US US11/497,888 patent/US7951384B2/en not_active Expired - Fee Related
- 2006-08-03 CN CN2006800370977A patent/CN101282744B/zh not_active Expired - Fee Related
- 2006-08-03 WO PCT/US2006/030319 patent/WO2007019247A2/en active Application Filing
- 2006-08-03 EP EP06800719A patent/EP1917033B1/en active Active
- 2006-08-03 AU AU2006278588A patent/AU2006278588A1/en not_active Abandoned
- 2006-08-03 KR KR1020087005392A patent/KR101120784B1/ko active IP Right Grant
- 2006-08-03 NZ NZ565961A patent/NZ565961A/en not_active IP Right Cessation
- 2006-08-03 BR BRPI0614702-0A patent/BRPI0614702A2/pt not_active Application Discontinuation
- 2006-08-03 CA CA2617508A patent/CA2617508C/en not_active Expired - Fee Related
- 2006-08-03 JP JP2008525192A patent/JP5342234B2/ja not_active Expired - Fee Related
- 2006-08-03 RU RU2008106445/13A patent/RU2008106445A/ru not_active Application Discontinuation
- 2006-08-03 AT AT06800719T patent/ATE528016T1/de not_active IP Right Cessation
-
2008
- 2008-01-31 US US12/012,175 patent/US9399059B2/en active Active
- 2008-02-05 IL IL189313A patent/IL189313A/en active IP Right Grant
-
2009
- 2009-04-07 HK HK09103268.0A patent/HK1125051A1/xx not_active IP Right Cessation
-
2013
- 2013-04-15 JP JP2013084501A patent/JP2013176375A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20070178120A1 (en) | 2007-08-02 |
CN101282744A (zh) | 2008-10-08 |
KR20080072627A (ko) | 2008-08-06 |
CA2617508A1 (en) | 2007-02-15 |
CN101282744B (zh) | 2012-01-04 |
WO2007019247A3 (en) | 2008-01-17 |
JP2013176375A (ja) | 2013-09-09 |
US9399059B2 (en) | 2016-07-26 |
KR101120784B1 (ko) | 2012-04-20 |
JP5342234B2 (ja) | 2013-11-13 |
CA2617508C (en) | 2013-12-31 |
RU2008106445A (ru) | 2009-09-10 |
JP2009502204A (ja) | 2009-01-29 |
IL189313A (en) | 2015-10-29 |
US20090068221A1 (en) | 2009-03-12 |
BRPI0614702A2 (pt) | 2011-04-12 |
EP1917033A2 (en) | 2008-05-07 |
US7951384B2 (en) | 2011-05-31 |
WO2007019247A2 (en) | 2007-02-15 |
IL189313A0 (en) | 2008-06-05 |
EP1917033A4 (en) | 2009-09-02 |
NZ565961A (en) | 2011-11-25 |
EP1917033B1 (en) | 2011-10-12 |
AU2006278588A1 (en) | 2007-02-15 |
ATE528016T1 (de) | 2011-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1125051A1 (en) | Virus-like particles as vaccines for paramyxovirus | |
WO2009105152A3 (en) | Virus-like particles as vaccines for paramyxovirus | |
MX2013008836A (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
SG153874A1 (en) | Neutralizing epitope-based growth enhancing vaccine | |
WO2006115843A3 (en) | Nipah virus vaccines | |
EA200700849A1 (ru) | Первичная/бустерная противомалярийная вакцина | |
WO2010039224A3 (en) | Respiratory syncytial virus (rsv) sequences for protein expression and vaccines | |
WO2008061243A3 (en) | Respiratory syncytial virus-virus like particle (vlps) | |
WO2002080851A3 (en) | Chimeric vaccines | |
NZ595736A (en) | Chimeric viruses presenting non-native surface proteins and uses thereof | |
EP1594536A4 (en) | ADJUVANT INFLUENZA VACCINE | |
WO2008103819A3 (en) | Chimeric newcastle disease virus vlps | |
WO2008156655A3 (en) | Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors | |
IN2012DN03928A (zh) | ||
EP2525816A4 (en) | PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES | |
BRPI0816134A2 (pt) | Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença. | |
WO2010074575A3 (en) | Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv. | |
WO2008148104A8 (en) | Novel vlps derived from cells that do not express a viral matrix or core protein | |
EP3156070A3 (en) | Newcastle disease virus vectored herpesvirus vaccines | |
WO2007008918A3 (en) | Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof | |
MX343830B (es) | Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma. | |
ATE516345T1 (de) | Von ibdv (infectious bursal disease virus) abgeleitete chimäre leere virusähnliche partikel, verfahren zu deren herstellung und anwendungen | |
WO2005081716A3 (en) | DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) | |
EA201100674A1 (ru) | Вакцина против вируса африканской чумы лошадей | |
GB2429711A (en) | Heart and skeletal muscle inflammation (HSMI) virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220806 |